65,437 trials
Low Back Pain · Low Back Pain, Recurrent · Musculoskeletal Pain
Primary: Change From Baseline (Mean of Three Measurements at Screening, Prior to Treatment Visit 1 and Treatment Visit 1 Pretreatment) in the Average Visual Analog Scale (VAS)…
Lower Back Pain
Primary: Physical Function — 62.04; 48.67 units on a scale
HIV Lipodystrophy
Primary: Overnight Mean Growth Hormone Secretion After 2 Weeks of Study Drug — 0.23; 0.07; 1.24 ng/mL — p=0.01
Precancerous Condition · Stage I Non-small Cell Lung Cancer · Tobacco Use Disorder
Primary: Percentage of Participants With Response Determined by Change in Histologic Grade of Bronchial Dysplasia as Measured by Mucosal Biopsy Samples Before and After Treatment…
Myopia
Primary: Slit Lamp Findings > Grade 2 — 0; 1 eyes
Hypertension
Primary: Number of Participants With Treatment Related Adverse Events. — 75 participants
Rosacea
Primary: Long Term Safety & Efficacy of CD07805/47 Gel 0.5% in Subjects With Moderate to Severe Facial Erythema Associated With Rosacea. — -1.5; -1.4; -1.5; -1.7 scores on a scale
Cervical Dystonia · Spasmodic Torticollis
Primary: Mean Change From Baseline in the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) -Total Score at Week 4 After Treatment — 3; 8.9; 7.6; 10.5 Points on a Scale
Disseminated HER2+ Breast Cancer
Primary: The Patient Clinical Profile (General Clinical Data and Breast Cancer Characteristics) — 63.5; 48.8; 84.1; 41.1 percentage of participants
Bipolar Disorder · Bipolar Depression · Depression
Primary: The Primary Outcome Measure Was Change in Montgomery-Asberg Depression Rating Scale (MADRS) Scores Over Weeks Between Groups. — 11.4; 5.9 Scores on a scale
Type 1 Diabetes Mellitus
Primary: Onset Time (Tmax) — 30; 52 Minutes
Myopia
Primary: End-of-day Comfort — 8.3; 6.6 Units on a scale
Osteoporosis
Primary: Adherence With Treatment in the First Treatment Period — 95; 111; 29; 15 Participants — p=0.0259
Cervical Ripening
Primary: Cervical Dilation in Women Following Exposure to Either Ripening Agent — 32.1; 33.9 mm
Cancer · Colon Cancer · Colorectal Cancer
Primary: Percentage of Participants With Grade 3/4 Febrile Neutropenia Across the First 4 Cycles of Chemotherapy — 5.7; 2.4 percentage of participants — p=0.014